UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of March 2022
Commission File Number: 001-39481
PainReform Ltd.
(Translation of registrant’s name into English)
4 Bruria St. Tel Aviv, 6745442
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
On March 17, 2022, PainReform Ltd. issued a press release entitled “PainReform Provides Year-End Business Update; On track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022”. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Exhibit Index
Exhibit No. | Description | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: March 17, 2022 | PAINREFORM LTD. | ||
By: | /s/ Ilan Hadar | ||
Ilan Hadar | |||
Chief Executive Officer |